Company Encyclopedia
View More
name
PURAPHARM
01498.HK
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong’s name that provide Chinese medicine services and CCMG products.
1.450 T
01498.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking45/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-33.22%E
    • Profit Margin-11.12%D
    • Gross Margin55.21%B
  • Growth ScoreD
    • Revenue YoY-17.32%E
    • Net Profit YoY55.73%B
    • Total Assets YoY-13.17%E
    • Net Assets YoY-22.09%E
  • Cash ScoreE
    • Cash Flow Margin-899.29%E
    • OCF YoY-17.32%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreE
    • Gearing Ratio85.02%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    PURAPHARM issued a total of 140 million shares

    According to the announcement from PURAPHARM, based on the patent licensing agreement dated July 25, 2025, the company will issue and allot 93,488,400 consideration shares on October 30, 2025. According to the subscription agreement dated July 25, 2025, the company will issue and allot 46,512,000 subscription shares on October 30, 2025

    Zhitong·
    HK
    01498
    +1.37%
    Zhitong·
    HK
    01498
    +1.37%

    PuraPharm Announces Board Composition and Roles

    PuraPharm Corp. Ltd. has announced its board composition and roles, clarifying its governance structure, which may influence its strategic direction and reassure stakeholders. The latest analyst rating for PuraPharm (HK:1498) is a Hold with a price target of HK$0.50. The company, based in the Cayman Islands, operates in the pharmaceutical sector, focusing on Chinese medicine products. Current market cap stands at HK$163.9M with an average trading volume of 184,991.

    Tip Ranks·
    HK
    01498
    +1.37%
    Tip Ranks·
    HK
    01498
    +1.37%

    PuraPharm Completes Key Share Transactions to Enhance Market Position

    PuraPharm Corp. Ltd. (HK:1498) has completed a Patent Licence Agreement and a Subscription Agreement, issuing 93,488,372 and 46,512,000 new shares respectively. These transactions significantly enhance the company's share capital and are expected to impact its financial structure and market position. The latest analyst rating for PuraPharm stock is a Hold with a price target of HK$0.50. The company, based in the Cayman Islands, specializes in herbal medicines and health products, with a current market cap of HK$163.9M.

    Tip Ranks·
    HK
    01498
    +1.37%
    Tip Ranks·
    HK
    01498
    +1.37%

    PURAPHARM appoints Dong Ziming as a non-executive director

    According to the Zhitong Finance APP, PURAPHARM announced that Mr. Dong Ziming has been appointed as a non-executive director, effective from October 30, 2025

    Zhitong·
    HK
    01498
    +1.37%
    Zhitong·
    HK
    01498
    +1.37%

    PuraPharm Appoints Dong Zimeng as Non-Executive Director

    PuraPharm Corporation Limited has appointed Mr. Dong Zimeng as a non-executive director, effective October 30, 2025. His nomination comes from Providence Discovery Fund under a recent subscription agreement. Mr. Dong holds degrees from the University of Warwick.

    Reuters·
    HK
    01498
    +1.37%
    Reuters·
    HK
    01498
    +1.37%
    © 2025 Longbridge｜Disclaimer